NHS England is developing a new Commercial Framework, outlining potential opportunities for commerci...
Read moreMaximising the cost-saving potential of biosimilars remains a topic of much interest to payers and p...
Read moreThis study investigates how gaps in the current evidence are linked to access restrictions and mitig...
Read morePharmaceutical companies are incorporating payer / HTA needs into their clinical and commercial laun...
Read moreThis study aims to understand the industry perspective on drivers and challenges for a successful la...
Read moreMedicine prices in Greece are set by the IRP. IRP is the process of using the prices in other countr...
Read moreIs the evidence base for high-cost CAR T-cell therapies Kymriah and Yescarta sufficient to be grante...
Read moreWe are delighted to say that we have received fabulous feedback, with responses from 15 industry exe...
Read moreZolgensma launched in May 2019 in the US for $2.1 million, whilst Zynteglo was launched in the EU in...
Read more